首页> 外国专利> ESTABLISHING CLINICAL-GRADE EXOSOME BANK BY DEVELOPING NOVEL ISOLATION, POTENCY PROTOCOLS, AND A NOVEL CRYOPROTECTANT SOLUTION

ESTABLISHING CLINICAL-GRADE EXOSOME BANK BY DEVELOPING NOVEL ISOLATION, POTENCY PROTOCOLS, AND A NOVEL CRYOPROTECTANT SOLUTION

机译:通过开发新型隔离剂,强效协议和新型低温保护液来建立临床级外显子库

摘要

A new way of establishing clinical-grade exosome banks includes breakthroughs on three fundamental pre-requisite criteria. These three breakthroughs are developing a novel protocol for isolating exosomes, developing a simple and rapid test to predict potency, and using a novel cryoprotectant solution, trehalose solution, to store exosomes. Conditioned media culture is clarified using the SYR2-U20 KR2i automated TFF system. The culture then undergoes two distinct concentration processes, after which the exosomes can be concentrated into 1 ml. Furthermore, a simple and rapid test can predict the potency of mesenchymal stem cell, derived exosomes in T cell suppression assay. A higher percentage of CD90 has been found to be correlated with higher suppression activity. These tests can be used for quality controls in clinical trial. Furthermore, the usage of trehalose solution increases the stability of exosomes and keeps their potencies over long periods of time.
机译:建立临床级外泌体库的新方法包括在三个基本先决条件上的突破。这三个突破正在开发一种用于分离外泌体的新颖方案,开发一种简单而快速的测试以预测功效,并使用新型的冷冻保护剂溶液海藻糖溶液来储存外泌体。使用SYR2-U20 KR2i自动TFF系统澄清条件培养基的培养。然后将培养物经历两个不同的浓缩过程,然后将外泌体浓缩成1 ml。此外,简单而快速的测试可以预测T细胞抑制试验中间充质干细胞衍生的外泌体的效力。已经发现较高百分比的CD90与较高抑制活性相关。这些测试可用于临床试验中的质量控制。此外,海藻糖溶液的使用增加了外泌体的稳定性,并长时间保持了它们的效力。

著录项

  • 公开/公告号US2019391136A1

    专利类型

  • 公开/公告日2019-12-26

    原文格式PDF

  • 申请/专利权人 MILAD RIAZIFAR;RICK SAGA;

    申请/专利号US201916282274

  • 发明设计人 MILAD RIAZIFAR;RICK SAGA;

    申请日2019-02-21

  • 分类号G01N33/50;G01N1/34;A01N1/02;

  • 国家 US

  • 入库时间 2022-08-21 11:22:31

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号